Europe, despite excellent science, lost its co-equal status in drug development to the U.S. due to restrictive pricing and lack of growth capital. These same challenges are now emerging in the U.S., threatening its innovation leadership as China accelerates its efforts.

There's a growing recognition that European governments can no longer just be regulators; they must actively compete for biotech investment and clinical trials. This requires treating their country's R&D environment as a product with an "attractive offering" to win against global competitors.

The huge funding gap for European biotech is structural. European institutional investors like pension funds allocate only 0.02% of their balance sheets to venture, compared to 2% in the US. This factor-of-100 difference creates a major hurdle for the ecosystem's ability to retain its champion companies.

Recent billion-dollar successes in the French biotech ecosystem, such as Abivax and Medincel, are largely credited to their management teams. These leaders often have significant experience working in the US and other countries. This global perspective enables them to develop assets for a worldwide market, navigate different regulatory environments, and attract international funding, breaking the mold of previously localized French biotechs.

Beyond funding and regulatory hurdles, Europe's restrictive drug pricing environment is a fundamental threat. It discourages pharmaceutical companies, including Europe's own, from investing in the region as they prioritize the more profitable US market. This ultimately undermines the entire local R&D ecosystem.

Europe's decentralized biotech ecosystem offers a major operational advantage over hubs like Boston. Lower competition for talent, lab space, and clinical trial sites allows startups to operate at 50% of the cost, coupled with pre-money valuations that are often 40% lower, creating significant capital efficiency.

Unlike their US counterparts, European biotechs have less access to large venture funds. This forces a culture of extreme capital efficiency and discipline. This need to be "cleverer, smarter with less people and less money" is a defining feature and potential advantage of the European ecosystem.

Thriving life sciences ecosystems in Ireland, the UK, and Massachusetts did not grow by accident. Their success is the result of deliberate, long-term government strategies, including tax incentives, shared R&D infrastructure like the UK's 'Catapult' network, and fostering deep connections between technology, hospitals, and capital.

The future biotech landscape is not US vs. China, but a "multipolar" world where savvy companies operate as "hybrid biotechs." They will selectively build bridges, cherry-picking talent, capabilities, and operational models across the US, Europe, and China to accelerate development.